#### **Executive Overview** Zim Laboratories Limited is an India-based, research-driven pharmaceutical company established in 1989, with a global footprint and a strong focus on **differentiated generics** and **innovative drug delivery solutions**. The company specializes in **oral solid dosage forms**, leveraging proprietary non-infringing technologies to develop complex, high-value products across key therapeutic areas. As of November 2025, Zim is witnessing a transformational phase marked by regulatory milestones, expanding international presence, and strategic diversification into **New Innovative Products (NIP)** and **Oral Thin Films (OTF)**—both critical to its growth strategy in regulated and pharmerging markets. --- ### **Core Business & Strategy** #### **Product Portfolio & Business Segments** Zim operates in two main business verticals: - **Pharmaceuticals (75% of FY25 revenue):** Includes both generic finished formulations (FF) and pre-formulation intermediates (PFI), such as pellets, direct-compression granules, and taste-masked powders. - **Nutraceuticals (25% of FY25 revenue):** Branded under **ZimUNat**, this segment includes science-backed supplements leveraging Zim’s proprietary delivery platforms. The company emphasizes: - **NIP (New Innovative Products):** Complex, differentiated generics designed to enter markets as first- or second-to-file generics. These accounted for **11.5% of total operating income in FY25 (₹437 million)**. - **OTF (Oral Thin Films):** Delivered via its patented **Thinoral®** platform. OTF revenues grew **42% YoY to ₹186 million**, contributing **4.9% of total operating income**. - **Combined NIP + OTF segment contributed 16.5% of total operating income in FY25**, up from 10.1% in FY24, highlighting the success of its innovation-led growth model. --- ### **Recent Key Developments (2025)** #### **✅ August 2025 – Tamsulosin + Dutasteride FDC Launch in Australia** - Received **marketing authorization from Australia’s Therapeutic Goods Administration (TGA)** for the fixed-dose combination of **Tamsulosin Hydrochloride and Dutesteride**, used to treat moderate-to-severe benign prostatic hyperplasia (BPH). - Launched commercially in Australia under the brand **ZIMTAS**, through its wholly owned Australian subsidiary. - This approval: - **Strengthens urology portfolio**. - Improves patient compliance by replacing two separate drugs with one daily dose. - Enables **future regulatory filings in APAC and global markets**. - Aligns with Zim’s strategy to **commercialize innovative differentiators in regulated markets**. #### **✅ July 2025 – Rizatriptan ODF Approved in Australia** - Received **TGA approval for Rizatriptan Benzoate Orally Disintegrating Films (ODF)**. - Offers **rapid onset, no need for water**, ideal for migraine patients experiencing nausea. - Approval marks Zim’s **first OTF product in Australia**. - Supports **commercial launch and regional filings across Asia-Pacific**. - Reinforces the **global scalability** of Zim’s Thinoral® platform. #### **✅ June 2025 – Strategic Expansion & Manufacturing Enhancement** - **Appointed regional leaders** in 5 key geographies to accelerate product registration and commercialization. - **Established local presence** in EU, Australia, and Scientific Office in UAE. - **Signed landmark OTF licensing agreement with a GCC partner**, enabling local manufacturing and expanding market access. - Completed two **major CapEx projects**: - **Urology NIP Suite**: Dedicated capacity for high-value NIPs. - **Liquid-in-Pellet Technology-based Nutraceutical Suite**. - Total CapEx in FY25: ₹365 million. --- ### **Regulatory & R&D Strength** #### **Regulatory Progress (FY25 Highlights)** - **Marketing Authorizations Secured in FY25**: - 6 for NIPs (including EU approvals for **Dimethyl Fumarate & Azithromycin Suspension**). - 7 for OTF products (including EU-wide approval for **Buprenorphine Sublingual Films** via partner **Neuraxpharm**). - 14 for Finished Formulations (non-EU markets). - **Dossier Filings**: - 23 NIP, 17 OTF, and 10 FF dossiers filed globally. - 5 NIP and 6 OTF filings in the EU. - Filings in Australia through **ZIMTAS Pty. Ltd.** #### **R&D Investment & Innovation** - **R&D Spend**: ₹333 million in FY25 (8.8% of operating income). - **R&D Center**: DSIR-recognized, housing over 90 scientists (including 2 PhDs and 76 postgraduates). - **Proprietary Technology Platforms**: - **MECT**: Micro-Emulsion Coating. - **PCFT**: Pellet Cold Forming. - **RGDRT**: Rapid Gelation Drug Release (alternative to OROS®). - **MAPOTAB**: Matrix Pore Forming Tablet for controlled release. - **Advanced OTF Technologies**: - **Thinoral®**: Core OTF platform (fast-dissolving, non-sticky strips). - **Spinoral®**: Improves bioavailability of poorly soluble drugs via nanotechnology. - **Printoral®**: Ensures dose uniformity, ideal for potent drugs like opioids. - **Sublingual Spray**: Needle-free delivery for peptides and hormonal therapies. --- ### **Global Operations & Subsidiaries** #### **International Subsidiaries and Offices** - **ZIMTAS Pty. Ltd. (Australia)**: Key hub for Oceania operations—product registration and commercialization. - **SIA ZIM Laboratories Limited (Latvia, EU)**: Manages EU filings and marketing. - **ZIM Laboratories FZE (Sharjah, UAE)**: Business development in MENA & Africa. - **ZIM Health Technologies Ltd (India)**: Central R&D arm (₹333 million investment in FY25). - **ZIM Scientific Office LLC, UAE**: Supports product registration and regional expansion in MENA. - Strategic presence in North America, Europe, Middle East, and Australia. --- ### **Growth Drivers & Market Positioning** #### **Revenue Streams & Business Model** - **Exports Drive 83% of Revenue**, with presence in over 50 countries. - **Licensing & Co-Development Income**: ₹98 million from NIP and OTF dossier licensing. - **Flexible Commercialization Strategies**: - Product supply with regulatory support. - Non-exclusive dossier licensing. - Manufacturing & supply agreements post-approval. - Focus on **high-margin markets**: EU, Canada, Australia, BRICS, Saudi Arabia, and the GCC. #### **Therapeutic Focus** - Core areas: **Urology, Gastroenterology, CNS, NSAIDs/Analgesics, Cardiovascular, Anti-infectives, and Vitamins**. - High-growth segments: - **Urology**: Supported by NIP and OTF platforms (e.g., Zimtas, Sildenafil ODF). - **Migraine**: Rizatriptan ODF launch in Australia and APAC. - **CNS & Pain**: Buprenorphine Sublingual Film (approved via Neuraxpharm in 24 EU countries). #### **Domestic Business** - Contributed **17% of FY25 operating income**. - Supplies high-margin generic formulations to: - **Government schemes**: Jan Aushadhi, CGHS, ESIC, Indian Railways. - State and central tenders with **buffered pricing against raw material volatility**.